AI-generated research brief — verify at source
Rituximab Meets Noninferiority to Ocrelizumab in Newly Diagnosed Relapsing MS
In the first phase 3 head-to-head trial comparing these two anti-CD20 therapies, rituximab was noninferior to ocrelizumab in suppressing MRI-detected disease activity, with 92.2% versus 94.8% of participants remaining free of new or enlarging T2 lesions over 18 months of active follow-up (risk difference −2.6 percentage points, 95% CI −9.4 to 4.3). The confidence interval’s lower bound remained above the prespecified noninferiority margin of −10 percentage points, confirming comparable MRI efficacy, though the small numerical gap favored ocrelizumab.
What Was Studied
The trial investigated whether rituximab, an off-patent anti-CD20 monoclonal antibody, is noninferior to ocrelizumab, a newer branded anti-CD20 agent, in preventing the accumulation of new or enlarging T2-weighted MRI lesions in adults with newly diagnosed relapsing multiple sclerosis and evidence of recent disease activity. Because head-to-head comparative data between these two mechanistically similar agents had been absent, the trial directly addressed a clinically critical gap in treatment decision-making.
How It Was Studied
The OVERLORD-MS trial was a phase 3, multicenter, double-blind, noninferiority randomized controlled trial conducted across multiple centers. Adults with newly diagnosed relapsing MS and recent disease activity were randomly assigned in a 3:2 ratio to receive either rituximab or ocrelizumab administered intravenously every 6 months over a 24-month treatment period. Of 218 participants randomized, 216 received at least one dose — 132 in the rituximab group and 84 in the ocrelizumab group. The primary MRI endpoint was assessed from month 6 through month 24, allowing an initial 6-month window for treatment to take full biological effect before lesion counting began.
What Was Observed
- Primary MRI endpoint met noninferiority: 92.2% of rituximab-treated participants and 94.8% of ocrelizumab-treated participants were free of new or enlarging T2 lesions between months 6 and 24, a difference of approximately 2.6 percentage points in favor of ocrelizumab (risk difference −2.6 percentage points, 95% CI −9.4 to 4.3). Because the lower confidence boundary did not cross the prespecified −10 percentage point noninferiority threshold, rituximab was confirmed noninferior.
- Clinical outcomes appeared comparable: Relapse rates, disability progression measures, and cognitive performance profiles appeared similar between the two treatment groups across the 24-month follow-up, suggesting alignment of clinical and radiological findings.
- Infections were more frequent with rituximab: 82% of rituximab participants experienced at least one infection compared with 69% in the ocrelizumab group — a numerically meaningful difference of 13 percentage points. However, the proportion of participants experiencing serious adverse events was nearly identical at 8% versus 7%, respectively, indicating that the excess infections in the rituximab arm were predominantly non-severe.
Why This Matters
Anti-CD20 monoclonal antibodies are described in the abstract as effective therapies for relapsing multiple sclerosis, yet no prior phase 3 head-to-head trial had directly compared rituximab and ocrelizumab. This trial fills that evidence gap by demonstrating that the two agents achieve broadly similar suppression of MRI disease activity and comparable rates of serious adverse events in newly diagnosed patients. The finding has direct relevance to treatment selection and prescribing policy, particularly given that rituximab — as an off-patent agent — may offer cost advantages in certain healthcare settings.
How to Read This Result
While the trial was rigorously designed as a double-blind phase 3 noninferiority study with a clearly prespecified margin, the relatively modest sample size of 216 participants and the 24-month observation window introduce uncertainty about whether comparability in efficacy and safety would hold over longer treatment durations or in broader patient populations.
Limitations
The abstract does not explicitly report study limitations.